ICYMI, this week we had news about a study of upadacitinib versus dupilumab in atopic dermatitis, the European Union's approval of bimekizumab for HS, and more.
Skin cancer risk classification lacks reliability for darker skin tones and fails in evaluating cutaneous medical conditions or cosmetic interventions, according to creators of the scale.